**Name of Journal:** ***World Journal of*** ***Gastroenterology***

**Manuscript NO: 43017**

**Manuscript Type: REVIEW**

**Alcoholic liver disease**: **Utility of animal models**

Lamas-Paz A *et al*. Modeling ALD

Arantza Lamas-Paz, Fengjie Hao, Leonard J Nelson, Maria Teresa Vázquez, Santiago Canals, Manuel Gómez del Moral, Eduardo Martínez-Naves, Yulia ANevzorova, Francisco Javier Cubero

**Arantza Lamas-Paz,** **Fengjie Hao, Eduardo Martínez-Naves, Francisco Javier Cubero,** Department of Immunology, Ophthalmology and ORL, Complutense University School of Medicine, Madrid 28040, Spain

**Arantza Lamas-Paz, Fengjie Hao, Eduardo Martínez-Naves, Yulia A Nevzovova, Francisco Javier Cubero,** 12 de Octubre Health Research Institute (imas12), Madrid 28041, Spain

**Leonard J Nelson,** Institute for Bioengineering (IBioE), School of Engineering, Faraday Building, The University of Edinburgh, Edinburgh EH9 3 JL, Scotland, United Kingdom

**Maria Teresa Vázquez,** Department of Human Anatomy and Embryology, Complutense University School of Medicine, Madrid 28040, Spain

**Santiago Canals,** Instituto de Neurociencias, Consejo Superior de Investigaciones Científicas, Universidad Miguel Hernández, San Juan de Alicante 03550, Spain

**Manuel Gómez del Moral,** Department of Cell Biology, Complutense University School of Medicine, Madrid 28040, Spain

**Yulia ANevzorova,** Department of Genetics, Physiology and Microbiology, Faculty of Biology, Universidad Complutense, Madrid 28040, Spain

**Yulia ANevzorova,** Department of Internal Medicine III, University Hospital RWTH Aachen, Aachen 52062, Germany

**ORCID number:** Arantza Lamas-Paz (0000-0001-5857-4320); Fengjie Hao (0000-0002-6734-265X); Leonard J Nelson (0000-0002-4197-4843); Maria Teresa Vázquez (0000-0003-3537-0901); Santiago Canals (0000-0003-2175-8139); Manuel Gómez del Moral (0000-0002-0642-8142); Eduardo Martínez-Naves ([0000-0001-8136-9042](http://orcid.org/0000-0001-8136-9042)); Yulia ANevzorova (0000-0003-1390-8002) and Francisco Javier Cubero (0000-0003-1499-650X).

**Author contributions:** Lamas-Paz A and Hao F equally contributed to the manuscript writing and figure design; Nelson LJ, Vázquez MT, Canals, S, Gómez del Moral M and Martínez-Naves E critiqued the manuscript, checked English language and provided fundamental guidance. Nevzorova YA and Cubero FJ outlined and corrected the review and provided guidance.

**Supported by** the MINECO Retos, No. SAF2016-78711 and SAF2017-87919R; EXOHEP-CM, No. S2017/BMD-3727; the AMMF Cholangiocarcinoma Charity, No. 2018/117; the COST Action, No. CA17112; Ramón y Cajal, No. RYC-2014-15242 and No. RYC-2015-17438; grant of ERAB, No. EA 14/18; Gilead Liver Research Scholar 2018, No. 44/2018; Ministerio de Sanidad, Servicios Sociales e Igualdad, No. 2017I065; and the UCM group “Lymphocyte Immunobiology”, No. 920631 (imas12-associated, Ref. IBL-6).

**Conflict-of-interest statement:** The authors declare that they have no conflict of interest.

**Open-Access:** This is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>

**Manuscript source:** Invited manuscript

**Correspondence to:** **Francisco Javier Cubero, BSc, MSc, PhD, Assistant Professor,** Department of Immunology, Ophthalmology and ORL, Complutense University School of Medicine, c/Doctor Severo Ochoa 9, Madrid 28040, Spain. fcubero@ucm.es

**Telephone**: +34-91-3941385

**Fax**: +34-91-394164

**Received:** October 19, 2018

**Peer-review started:** October 19, 2018

**First decision:** November 1, 2018

**Revised:** November 8, 2018

**Accepted:** November 9, 2018

**Article in press:**

**Published online:**

# Abstract

Alcoholic liver disease (ALD) is a major cause of acute and chronic liver injury. Extensive evidence has been accumulated on the pathological process of ALD during the past decades. However, effective treatment options for ALD are very limited due to the lack of suitable *in vivo* models that recapitulate the full spectrum of ALD. Experimental animal models of ALD, particularly rodents, have been used extensively to mimic human ALD. An ideal animal model should recapitulate all aspects of the ALD process, including significant steatosis, hepatic neutrophil infiltration, and liver injury. A better strategy against ALD depends on clear diagnostic biomarkers, accurate predictor(s) of its progression and new therapeutic approaches to modulate stop or even reverse the disease. Numerous models employing rodent animals have been established in the last decades to investigate the effects of acute and chronic alcohol exposure on the initiation and progression of ALD. Although significant progress has been made in gaining better knowledge on the mechanisms and pathology of ALD, many features of ALD are unknown, and require further investigation, ideally with improved animal models that more effectively mimic human ALD. Although differences in the degree and stages of alcoholic liver injury inevitably exist between animal models and human ALD, the acquisition and translational relevance will be greatly enhanced with the development of new and improved animal models of ALD.

**Key words:** Alcoholic liver disease; Reactive oxygen species; Steatohepatitis; Cirrhosis; Hepatocellular carcinoma

**© The Author(s) 2018.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Core tip:** Alcoholism is now considered a global health issue. Although significant progress has been made in our understanding of the mechanisms and pathology of alcoholic liver disease (ALD), many features of ALD remain unidentified - requiring further investigation with improved animal models that more effectively emulate human ALD. In this Review, we provide an update on the prevalence, current and emerging experimental models, as well as the pathophysiology of ALD.

Lamas-Paz A, Hao F, Nelson LJ, Vázquez MT, Canals S, Gómez del Moral M, Martínez-Naves E, Nevzorova YA, Cubero FJ*.* Alcoholic liver disease: Utility of animal models. *World J Gastroenterol* 2018; In press

# INTRODUCTION

Alcohol has been part of human culture for thousands of years. Excessive alcohol consumption is the oldest form of liver injury known to civilization. Currently, alcohol abuse is an important global health problem with a significant socioeconomic burden in most societies. The term alcoholic liver disease (ALD) comprises a range of disorders including simple steatosis, steatohepatitis, cirrhosis, and end-stage hepatocellular carcinoma (HCC).

Animal models are frequently used to emulate and understand the underlying mechanisms of human disease. However, over the last decades, a great variety of animal models for ALD have been developed with different outcomes. To find the “ideal” experimental model for ALD would greatly help the study of the pathogenesis and thus development of new therapeutic strategies for the treatment of ALD. However, most models do not recapitulate the full spectrum of human ALD. A clinically-relevant model should induce certain characteristics, including: severe steatosis, hepatocellular damage and hepatic infiltration.

This review provides an overview of the pros and cons of the most frequently used experimental models of ALD, and the advances and implementation of new animal models that show great potential. We also discuss the recapitulation of pathological events in such models that commonly occur in human ALD.

# PATHOPHYSIOLOGY OF ALD

Alcohol abuse has a long history although it was not until the 20th century when it was studied with a scientific perspective. In 1965, pioneering work by Lieber and colleagues[[1](#_ENREF_1)] identified the hepatotoxic function of alcohol, instead of the malnutrition effect, previously assumed. ALD is now recognized as a complex disease induced by alcohol abuse with a broad spectrum of liver diseases. These range from simple steatosis to more severe forms of injury, including steatohepatitis, cirrhosis and HCC[[2](#_ENREF_2),[3](#_ENREF_3)].

Following absorption in the gastrointestinal tract (GI), only 2% to 10% of total ingested ethanol is directly eliminated through the lung, the kidney and sweat in an unchanged form[[4](#_ENREF_4)]. Most ethanol will undergo metabolic processing in the liver (Figure 1). First, ethanol (C2H6O) is oxidized and transformed into acetaldehyde (C2H4O) in hepatocytes. This step is mainly achieved by the enzyme alcohol dehydrogenase (ADH); although alternative minor pathways are involved including the catalase enzyme pathway (which has low expression in the liver), and the microsomal ethanol oxidation system (MEOS) - which depends on cytochrome P450 (CYP450) enzymes, particularly cytochromes P450 2E1 (CYP2E1)[[4](#_ENREF_4)]. Successive oxidation reactions take place: Acetaldehyde loses hydrogen, and is metabolized to acetate (C2H3O), under the catalysis of acetaldehyde dehydrogenase (ALDH). Major reactions in this process require the coenzyme nicotinamide adenine dinucleotide (NAD+) for transferring hydrogen, and the amount of reducing equivalents (NADH) is increased as a result. It has been reported that the change in NAD+/NADH ratio favours hepatic triglyceride accumulation and fatty acid synthesis[[4](#_ENREF_4)].

Another feature of alcohol metabolism is the generation of reactive oxygen species (ROS), which are largely regulated (and which can be exacerbated) by the CYP2E1 family[[5](#_ENREF_5)]. These active radicals are usually produced by the mitochondria, endoplasmic reticulum (ER) or Kupffer cells (KCs). They rapidly form a variety of active metabolites which can further contribute to oxidative stress in hepatocytes[[6](#_ENREF_6)]. Last but not least, acetaldehyde, the major metabolite of ethanol, is a powerful hepatotoxin. Multiple studies indicate acetaldehyde-induced liver injury *via* mechanisms that promote glutathione depletion, ROS toxicity and lipid peroxidation[[7-9](#_ENREF_7)] (Figure 1).

Thus, ethanol metabolism can lead to direct biochemical changes in hepatocytes, including cytotoxic metabolites, accumulation of ROS and lipid peroxidation. Importantly, all of these effects can further trigger complex pathological responses that eventually cause damage in the liver. Patterns involved in alcohol-induced liver injury include inflammation, different types of cell death (mainly apoptosis and necrosis), steatosis, fibrogenesis, and even liver regeneration (Figure 2).

Statistically, only about the 35% of ALD patients go on to develop ALD with liver fibrosis. Alcohol-induced damage in liver significantly increases the production of cytokines, chemokines, other soluble mediators and components of the innate immune system[[10](#_ENREF_10),[11](#_ENREF_11)]. This pro-inflammatory environment causes the activation of hepatic stellate cells (HSCs) and myofibroblasts, increasing the production of extracellular matrix (ECM) proteins, which can subsequently induce fibrogenesis in the liver[[12](#_ENREF_12)]. HSC is the main source of ECM proteins but also a critical target in alcoholic liver fibrosis. Acetaldehyde and adducts such as malondialdehyde (MDA) or 4-hydroxynonenal (4-HNE) directly affect HSC activation and collagen-I genes *via* different signalling cascades[[13](#_ENREF_13)]. Another crucial mechanism of alcohol-promoting liver fibrosis is associated with endotoxin and immune responses. Studies have shown correlation between alcohol administration, endotoxin in blood and KCs[[14](#_ENREF_14)]. In the intestine, alcohol impairs tight junctions (TJs) - increasing gut permeability between epithelial cells, thus allowing the gut-derived bacterial endotoxin, lipopolysaccharide (LPS), to enter the liver *via* the portal vein[[15](#_ENREF_15)]. It is common to see increased levels of serum LPS in ALD patients. KCs, the principal immune cells in the liver, are involved in this process. Several studies have shown that increased LPS levels induced by alcohol stimulate KCs to generate ROS and cytokines. These inflammatory mediators subsequently activate HSCs *via* a Toll-like receptor 4 (TLR4) signalling pathway, which eventually results in enhanced, chronic production of ECM proteins - and promotion of fibrogenesis[[16](#_ENREF_16),[17](#_ENREF_17)]. Additionally, HSCs are also enriched with TLR4 that directly bind, and thus activate through LPS signalling[[18](#_ENREF_18)]. To summarize, alcohol-stimulated liver fibrosis is a result of a robust immune response involving many types of liver cells and different signal transduction pathways. Fibrosis can develop into alcoholic cirrhosis, which is an advanced stage of liver fibrosis (occurring in 8%-20% of heavy drinkers) – this event is a significant risk factor for HCC. Such pathophysiological transitions will certainly reveal unique mechanisms, requiring more detailed studies and more realistic models[[19](#_ENREF_19),[20](#_ENREF_20)].

# HISTORY OF EXPERIMENT MODELS

The use of animals as models for scientific study is a very old practice of human civilization. Acquiring knowledge and experience from his predecessors, Galen of Pergamum (2nd century BC), a Roman physician, greatly improved techniques for dissection and vivisection of animals, and further used them to study cardiovascular and neural anatomy extensively[[21](#_ENREF_21)].

However, landmark findings in anatomy and physiology in ancient times were largely based on observation, inference and extrapolation of animal physiology to humans.

A Flemish anatomist, Vesalius (1514-1564), a physician and surgeon, was also a pioneer in animal modelling. He compared the similarity and differences between human body and other animal species, overturning the work of Galen – dogma which held for nearly 2000 years. He also recognized the value of animal experiment in teaching and performed vivisection of animals for medical students at his courses. Among the list of new, animal experimentalists, were scholars such as William Harvey (1578-1657). Using results from elegant and sophisticated experiments on live animals, Harvey published his revolutionary work *De Motu Cordis* in 1628, in which he described the anatomic and functional properties of the heart and vascular system from many species with remarkable accuracy[[22](#_ENREF_22),[23](#_ENREF_23)].

The 20th century has witnessed unprecedented advances in biological and medical science. Innovations such as the invention of antibiotics, new diagnostic methods and surgical techniques, chemo- and radio-therapy for cancer, and improved vaccination. Saving millions of lives and significantly increased the average life expectancy. In the past few decades, the use of animal modelling increased dramatically - further supporting the development of medical science. Currently, animal species (model organisms) frequently used in laboratories include: rodents (mouse and rat), zebrafish, swine, rhesus, guinea pig, rabbit, cat, and dog. However it is mammalian rodent models that are the most frequently used - several important advantages: (1) Rodents are highly-resistant to successive in-breeding, with less genetic variability between individual animals (and generations); (2) Their short lifespan and a fast rate of reproduction allows more rapid accumulation of data; (3) Rodents are small in size and easy to handle for most experimental procedures; and (4) Costs are low per animal in terms of initial purchase cost, housing and maintenance. Altogether, rodents provide a model system for study of alcohol effects on mammalian physiology, are amenable to a tremendous array of experimental questions, and are highly-efficient in both time and budget.

Transgenics has become an important tool for generating animal models of human disease. Transgenics involves the addition of foreign genetic information (nucleic acids) to animals, often for specific inhibition of endogenous gene expression. However, despite the generation of several transgenic and knockout models, the development of relevant models has theoretical and technical challenges. Indeed, many ALD-associated genes of interest have not been fully identified and gene addition or inactivation can yield inconclusive results. Some models relevant to ALD are transgenic mice for human CYP2E1 and p47 phox NADPHoxidase-deficient mice[[24](#_ENREF_24)].

# CURRENT EXPERIMENTAL MODELS OF ALD

Early attempts of studying ALD with animal models began in the 1950s – using primarily rodents (mice, rats, hamsters, guinea pigs), and primates. An early study using six animal species in parallel was designed to detect their voluntary consumption of alcohol[[25](#_ENREF_25)]. The data interestingly suggested that golden hamster had a clear preference for alcohol solution (about 88% of their total liquid intake amount), while all other species significantly prefer water over alcohol (with rabbits as the only exception that consumed both drinks at comparable levels). In another study, baboons receiving alcohol-containing diet for 3-4 years, all developed severe hepatic injury (liver fibrosis or cirrhosis), which closely resembled all the pathological stages of human ALD. Thus primates are considered an ideal animal model of studying ALD[[26](#_ENREF_26)]. However, ethical issues, and the now very tight regulatory controls on the use of primates, as well as high cost and time, prevent the use of primates for the study of ALD in most laboratories. Thus, although rodents (mainly mice and rats), are still the preferred animal species to mimic ALD in human, such models fail to display the complete disease spectrum of human ALD[[27](#_ENREF_27),[28](#_ENREF_28)].

Various hypotheses have been proposed to explain the disparity in liver injury between human and rodents after ethanol exposure. Notably, most rodents have a natural aversion to alcohol and tend to consume ethanol only for calories rather than for craving. In addition, the catabolic rate in rodents is 5 times faster than in humans[[29](#_ENREF_29)]. These characteristics lead to less damage in rodents, after alcohol exposure, than humans. In addition to effects of alcohol metabolism, difference in the innate immune systems must be carefully considered as immune responses and the pattern of inflammation all play a critical role in the pathology of ALD. For example, the balance between neutrophils and lymphocytes in the blood differs greatly in mice and humans: neutrophils account for 50%-70% of total leukocytes in human blood (10%-25% in mice); whereas lymphocytes comprise 75%-90% of leukocytes in mouse blood, compared with 30%-50% in humans[[30](#_ENREF_30)]. The physio-/pathophysiological consequences of these differences remain largely unknown. Studies have however demonstrated that mice exhibit greater resistance against endotoxin-induced inflammation, thus experiments usually require a higher ethanol challenge to create the extent of damage comparable with humans[[31](#_ENREF_31)].

The response to alcohol and the development of ALD in humans varies considerably between individuals, and ethnic groups. Besides familiar risk factors such as age, diet, and smoking - genetic differences among individuals or ethnic groups are also of great significance. A genotyping study in Asian populations, showed that approximately 50% of Chinese and Taiwanese have low ALDH activity compared with Western nations, due to different genetic polymorphisms in the ALDH2\*2 allele[[32](#_ENREF_32)]. Similarly, diverse outcomes after receiving alcohol application are also seen in different rodent strains. In one case study, mice from 14 commercially acquired inbred strains received ethanol diet (up to 27 mg/kg body weight per day) with an intragastric enteral feeding model for 28 d; all strains exhibited comparable caloric intake and blood alcohol concentration (BAC) levels after the feeding[[33](#_ENREF_33)]. Interestingly, mice from strains NZW/LacJ, C57BL/10J, FVB/NJ, BALB/cByJ showed severe liver injury compared with mice from WSB/EiJ, PWD/PHJ, C3H/HeJ, AKR/J strains. These results indicated that the marked difference in sensitivity to alcoholic liver injury, was strongly dependent on the mouse strain. Thus, careful consideration of the strain/ desired traits and experimental outcomes should be undertaken when considering an experimental model of ALD. In another study, rats from three different strains (Long Evans, Sprague Dawley, Fisher 344) were fed with an isocaloric liquid diet containing ethanol (equivalent to 37% of the total caloric intake) for 8 wk[[34](#_ENREF_34)]. All three strains exhibited equally increased BAC, but significantly varied in body weight, alanine aminotransferase (ALT), triglycerides and cholesterol levels. Notable differences were also found in proinflammatory parameters including TNF-α, IL-6 and interleukin-1beta (IL-1β), indicating different degrees of hepatic inflammation after alcohol administration among the three strains. Moreover, dramatic variations were detected between the three strains in some critical enzymes of ethanol metabolism including ADH1, ADH2, AHD3, Catalase, and CYP2E1, suggesting the inequality of alcoholic liver damage may be partly due to different rates of ethanol metabolism between all strains.

Numerous models employing rodent animals have been established to investigate the effects of acute and chronic alcohol exposure on the initiation and progression of ALD (Table 1). To achieve the desired animal model of alcohol disorder, consideration should be given to such factors as amount, route and duration of ethanol given to the animal, and, as mentioned above, the particular animal strain. The amount and duration of ethanol applied to the animal should be sufficient to maintain both a consistently high level of BAC, and long enough to create an acute or chronic injury. In addition, the route of alcohol delivery also plays a critical role in determining the effect of a model. Studies of alcohol administration using vapour inhalation, intravenous, or intraperitoneal injection have been widely reported. These approaches can overcome the unwillingness to imbibe alcoholic beverage in most rodents, and accurately control the amount of ethanol absorbed. However, despite the high level of BAC in rats and mice, these models fail to mimic the natural alcohol “drinking” *i.e. via* the oral route, ingestion and subsequent metabolic processes in humans. As a result, such models are more frequently employed in the field of addiction and behavioural studies, rather than in studies related to alcoholic-induced liver damage[[35-37](#_ENREF_35)].

Focusing on the effects of alcohol on the GI and liver, rodent models of oral alcohol ingestion have been developed and extensively utilized. By engaging the rodents in “voluntary drinking”, these approaches largely replicate the overall process of human drinking habits as well as the general effects of alcohol on liver and intestine. Patterns of alcohol exposure in humans include both short-/ and long-term drinking. Whilst acute liver injury occurs even after 4-5 acute or binge episodes, within a period of several hours, chronic damage accumulates over many years of continuous ethanol consumption. In rodents, gastric intubation is commonly used to administer ethanol dosages of 4-6 g/kg body weight to induce acute hepatic injury. One study using this approach, followed by LPS injection, demonstrated that acute ethanol administration exacerbated hepatic damage caused by endotoxin[[38](#_ENREF_38)]. Compared with acute animal models using only one or a few gavages, chronic models of alcohol feeding typically last 4-12 wk, usually with a specially designed diet. As acute and chronic alcoholic injury in the liver share remarkable overlap in their pathology, an increasing number of studies combine both models (chronic plus binge model), to better emulate current drinking patterns in humans.

# 

# *Lieber-DeCarli liquid diet*

One of the earliest and most successful diets designed specifically for studying the effect of alcohol consumption *in vivo* is the Lieber-DeCarli liquid diet. It was first introduced by Lieber *et al*[[39](#_ENREF_39)] in 1963 in response to the need for a more accurate *in vivo* research model for ALD. In a previous study, rats received a 15% (v/v) solution of ethanol instead of drinking water for 177 d. Afterwards, no obvious liver injury (including steatosis and fibrosis) were found in the ethanol-only feeding groups but mainly in groups fed also with a diet of nutritional deficiency[[40](#_ENREF_40)]. The investigators suggested that the damage to liver after alcohol consumption was a consequence of malnutrition. Thus, it was widely accepted that alcohol alone has no hepatotoxic risk.

In 1960s, in a series of studies, Lieber *et al*[[1](#_ENREF_1),[41-43](#_ENREF_41)] designed a diet containing ethanol and other nutritional components. They demonstrated that when rats received adequate diet, the absorption of alcohol was insufficient to cause significant liver damage, due to their natural aversion to ethanol. This aversion can be overcome when rats had access only to an ethanol-containing liquid diet formula but with no other food or drink. In this case, the daily intake of ethanol in rats can reach 12-18 g/kg, which was two to three times more than that achieved from drinking the ethanol-only solution. Notably, higher BACs were also observed (100 to 150 mg/dL)[[39](#_ENREF_39),[44](#_ENREF_44),[45](#_ENREF_45)]. Using this approach, in seminal work, Lieber *et al*[[46](#_ENREF_46)] observed significant steatosis in the liver and concluded that alcohol alone is a pathological factor that can induce liver disease. In the next decade, they further detected that this process was influenced by other factors such as gender, dietary fat, the essential nutrients methionine and choline, and vitamin A. These findings opened a new era for ALD research. The liquid diet formula in these studies later became known as the Lieber-DeCarli ethanol (LDE) and Lieber-DeCarli control (LDC) diets, and are now a standard experimental model for the study of ALD[[47](#_ENREF_47)].

The Lieber-DeCarli diet is an isocalorically-controlled liquid diet in that the total caloric content (0.6-1.0 cal/mL) in the diet remains unchanged, while specific components vary to serve different groups and experimental objectives. The LDC diet, often used for pair-fed control groups, is formulated from several key parts of nutrition: Casein (consisting of methionine and cystine), contributes 18% of total calories; fat, derived from olive and corn oils, makes up 35% of total calories; fat-soluble vitamins(A, D, E, K) and water-soluble vitaminB12, minerals and fiber; the remaining formula (dextrin and maltose mixture) provided the majority of energy (47% of the total calories)[[42](#_ENREF_42),[44](#_ENREF_44),[45](#_ENREF_45)]. In the ethanol-containing formula (LDE diet), an amount equal to 36% of total calories of the dextrin and maltose mixture is removed and replaced by isocalorically measured alcohol[[42](#_ENREF_42),[44](#_ENREF_44),[45](#_ENREF_45)]. Of note, when applying the LDE diet, the amount of ethanol in the diet should be increased gradually during a primer period of approximate five days, in which the concentration of ethanol increases from zero to the final concentration (in most studies 50 g/L). This short priming period allows the animal to adapt to the ethanol-contained diet gradually, thus ensuring the effect of subsequent formal feeding.

The feeding period using the LDE model usually varies from 4 wk to 12 wk in mouse and 1-9 mo in rat[[48-58](#_ENREF_48)]. In most studies, there was a marked elevation of serum ALT and aspartate aminotransferase (AST), with a 6-fold average increase in hepatic triglycerides[[46](#_ENREF_46)]. Moreover, varying degrees of hepatic steatosis was widely observed in the experimental group. However, no other major hepatic pathological changes, particularly severe forms such as fibrosis, have been reported with the LDE diet feeding model, including long feeding periods of up to nine months in rat[[58](#_ENREF_58)]. A possible explanation for this limitation is that the LDE diet can only maintain a relatively low BAC in animals, compared with other feeding models such as patients with advanced stage ALD[[27](#_ENREF_27)].

Many attempts have since been made to elevate the effect of LDE diet - to induce more sever forms of liver injury, in order to overcome its limitations. The general aim would be better mimicking the pathogenesis of ALD in human, in particular its advanced forms. It is not rare for physicians to observe that advanced alcoholic hepatitis (AH) occurs in patients who have a long history of chronic drinking, but also have one or several more recent heavy binge drinking experiences[[59](#_ENREF_59),[60](#_ENREF_60)]. In this context, the chronic-binge ethanol feeding rodents model, which combines a chronic feeding period using LDC diet and one or multiple binges has been introduced and widely accepted[[28](#_ENREF_28)]. To perform this model, the LDE diet (5% v/v) is given for four weeks to create chronic liver injury as described above. In addition, single or multiple binges are applied by intragastric gavage twice a week during the chronic feeding phase. For gavage, absolute ethanol is diluted to 32% (v/v) in tap water and the recommended dosage of alcohol is calculated at 5 g/kg body weight[[61](#_ENREF_61)]. It has been reported that in this model, the BAC in rodents can reach 200 to 500 mg/dL, with remarkable elevation of transaminases in serum and significant steatosis in liver[[60](#_ENREF_60),[62](#_ENREF_62)].

Besides binge drinking, other hepatotoxins can subsequently be added during the chronic feeding phase of the LDE diet to provide a “second hit” and increase liver damage, such as: diethylnitrosamine (DEN), LPS, carbon tetrachloride (CCl4), or acetaminophen (APAP)[[63-66](#_ENREF_63)]. These studies have expanded the use of the LDC diet and provided useful insight into the effects of ethanol on the initiation and progression of severe liver injuries such as cirrhosis or HCC.

# *Ethanol ad libitum feeding*

The *ad libitum* alcohol feeding model was one of the earliest animal models used for ALD study in rodents[[40](#_ENREF_40)]. Alcohol is administrated in tap water serving as the only source of drinking water for animals, whilst animals have free access to a standard rodent chow diet. The *ad libitum* feeding model is simple to perform, and easy to manipulate the precise concentration of ethanol in the water. The ‘voluntary’ consumption of alcohol with the normal diet mimics the typical drinking pattern in humans; *i.e.* intermittent alcohol use with ordinary food intake. Partly due to its great flexibility, protocols used in different studies have varied considerably. The concentration of ethanol solution varied from 10%-40% (v/v), and the period of alcohol administration used in different groups can range from 8 weeks, and up to 70 wk, without significant mortality[[67-70](#_ENREF_67)]. In most studies, the *ad libitum* feeding model is sufficient to induce liver damage with clear steatosis and elevation of ALT and AST, but without more advanced lesions of fibrosis or cirrhosis[[68](#_ENREF_68),[70](#_ENREF_70),[71](#_ENREF_71)].

Despite its convenience, *ad libitum* feeding method has limitations compared to other ALD animal models. Noticeably, rodents show strong natural aversion to alcohol, as they tend to drink less ethanol than expected[[25](#_ENREF_25)]; whilst the rate of alcohol metabolism in rodents is much faster than in humans. These factors prevent the rats or mice from achieving high BAC consistently after chronic ethanol *ad libitum* feeding. The relatively low levels of BAC may be one of the main reasons for some misconceptions of early ALD studies[[40](#_ENREF_40)]. Mice receiving ethanol *ad libitum* of 20% (v/v) alcohol solution for eight weeks reached BACs between 50-70 mg/dL[[67](#_ENREF_67)]. Whereas only moderate increase in serum ethanol (to 90 mg/dL) was reported in an early study, where rats were given 40% ethanol solution daily, up to 29 wk[[68](#_ENREF_68)]. High BAC (up to 150 mg/dL) was also reported indicating wide variations of BAC after ethanol *ad libitum* application[[72](#_ENREF_72)]. Unlike the LDC diet, which is a nutrition-balanced diet ensuring equal calories in the presence or absence of alcohol content, it is very challenging to evaluate the nutritional status when applying *ad libitum* feeding.

Although the ethanol *ad libitum* feeding model is useful as a “standalone” model of mild alcoholic liver injury, an increasing number of studies combined it with other stressors to stimulate inflammation, fibrosis or HCC in liver. Noticeably, consistent long-term feeding can be substituted by *ad libitum* feeding for long-term periods of time due to its low mortality rate. In one study, 15 different mouse strains were tested with ethanol *ad libitum* from 8 wk to 78 wk[[69](#_ENREF_69)]. More recently, secondary factors have been introduced including other dietary models such as the high-fat diet and high-fructose diet, to evaluate whether such dietary factors potentiate chronic alcohol-induced liver injury[[70](#_ENREF_70),[73](#_ENREF_73)]. Other studies combining ethanol *ad libitum* feeding model with well-known hepatic stressors like DEN, diallyl disulphide (DADS), phenobarbital, and CCl4 -typically induced advanced liver injury, including inflammation, fibrosis and HCC[[67](#_ENREF_67),[72](#_ENREF_72),[74](#_ENREF_74),[75](#_ENREF_75)]. In summary, ethanol *ad libitum* feeding is a simple and reproducible approach to introduce alcohol in rodents, is amenable to the introduction of secondary hits - and is thus widely used by many laboratories for ALD study.

# *The Tsukamoto-French intragastric infusion model*

Although oral alcohol administration including *ad libitum* feeding and ethanol-containing LDC diet has proved a convenient and effective way to apply alcohol in rodents, it has several limitations. Generally, the average BAC of rodents received oral alcohol administration is usually observed below 150 mg/dL, compared with human levels. Moreover, liver steatosis is the major pathological change in studies conducting oral ethanol application (without a second stressor), where no fibrosis or cirrhosis is found. To overcome these limitations, a new feeding model of direct infusion through a surgically implanted intragastric cannula was developed in 1984, also known as Tsukamoto-French (TF) model[[76](#_ENREF_76),[77](#_ENREF_77)].

Compared with other feeding models of oral administration, the TF infusion model has several distinct advantages. By circumventing the natural aversion to alcohol that generally exists in rodent animals, the TF model removes the barrier on the amount of alcohol that is consumed by the animals. An early study employed liquid diet with alcohol (reaching as high as 49% of total calories) with 30-d infusion. Rats developed severe hepatic steatosis and focal necrosis with a high average BAC (216 mg/dL), and highly elevated ALT and AST levels[[78](#_ENREF_78)]. More importantly, the TF model also allows easy manipulation of the food content in order to create the desired model of liver damage. When progressively increased ethanol intake (32%-47% of total calories), combined with high fat diet (25% of total calories as fat), fibrosis started to develop in rats within 30 d of feeding, and was observed in all animals after 120 d of feeding[[79](#_ENREF_79)]. Furthermore, this group also showed that by adding carbonyl iron (0.25% w/v) into the high fat/ ethanol-containing diet - by the end of 16 wk most mice developed fibrosis, to different extents, whilst 2 out of the 20 mice developed liver cirrhosis[[80](#_ENREF_80)].

Even after only 4 wk of intragastric infusion, the average BAC in mouse experiment can reach as high as 300-350 mg/dL, and peak BACs above 400 mg/dL can occur. This reflects a substantially greater level of alcoholic intoxication, achieved by the TF infusion model, over other alcohol feeding regimes[[81](#_ENREF_81)]. Altogether, in rodents the TF model produces a sequence of liver damage that closely resembles human ALD, *i.e.* progressive steatosis, fibrosis, cirrhosis with focal necrosis and immune cell infiltration[[82](#_ENREF_82)].

There are however several potential drawbacks of the TF model. First, the implantation of intragastric tube requires high technical and surgical competences in small animal handling and surgery. Extensive and stringent post-operative care is also essential as early contamination can increase mortality. In addition, the post-operative maintenance work can be a challenge, as the infusion cannula is usually kept *in situ* often for 2-3 mo. The open access nature of the cannula increases the possibility of infection and irritation that may affect the results or result in death. Therefore, animal health and welfare, physiological signs and any pathological changes demand close monitoring. These stringencies make the TF an expensive model that cannot be performed by all laboratories. However, rats with implanted cannula (TF model) and daily food infusion have been kept and maintained for as long as 6 months, indicating once achieved successfully, the intragastric infusion can be a reliable model for investigating experimental dietary conditions in ALD[[83](#_ENREF_83)].

As a feeding model initially designed for studying ethanol intake in rodents, the TF model has actually produced results with more severe alcoholic liver injury than in other alcohol administration methods. Additionally, the TF model has also been employed in studies focusing on obesity-associated disorders such as non-alcoholic fatty liver disease (NAFLD)[[84](#_ENREF_84)]. To sum up, the TF rodent model is an effective and reliable approach for ALD study as well as studies related to other metabolic complications associated with diet.

***The National Institute on Alcohol Abuse and Alcoholism NIAA model***

The group of Gao *et al*[[28](#_ENREF_28)] developed a chronic-plus-binge alcohol feeding mouse model in 2013 (Table 1). This model mimics acute-on-chronic alcoholic liver injury in patients. The model consists of 5 d of adaptation to the liquid diet. Subsequently, mice are fed a LDE containing 5% (v/v) ethanol for 10 d. A single dose of ethanol (5 g/kg body weight) is given at day 11 and 9 h later animals are euthanased. This model specifically triggers high levels of alcohol in blood, liver injury, fatty liver and inflammation.

The NIAA model has since been modified: A single binge (5 g/kg) or repeated intragastric infusions of alcohol (5 g/kg, 32% v/v, 3 doses, 12-h intervals) were added following chronic feeding with the LDE diet (5% v/v, 4-7 wk). The advantage of this modification is that the binge increases the neutrophil infiltration in mice[[47](#_ENREF_47)].

# COMPARISON OF HUMAN AND MURINE ALD

Although there are several mouse models of ALD, differences exist between human and mouse in mild and early forms of ALD.

In human ALD, serum liver function tests and liver histology analyses reveal high concentrations of the enzymes ALT and AST, steatosis, ballooning of hepatocytes, neutrophil infiltration and Mallory-Denk hyaline inclusions in the liver[[28](#_ENREF_28)]. Nevertheless, mouse models of mild and early ALD do not reflect the observed human pathology at each stage.

The model of *ad libitum* feeding with the LDC ethanol diet in mice for 4 wk, results in only mild steatosis and minor elevation of serum ALT, with low-level inflammation[[85-89](#_ENREF_85)]. Twelve weeks of stepwise feeding with the LDC diet containing ethanol shows fatty liver, but mild elevation of ALT in serum.

The TK model induces severe steatosis, mild liver inflammation and mild fibrosis through continuous intragastric feeding. This model is very useful for the study of ALD pathogenesis (Figure 2), but, as mentioned, it is expensive, has technical limitations and requires intensive medical care[[77](#_ENREF_77),[78](#_ENREF_78),[90](#_ENREF_90),[91](#_ENREF_91)].

Acute gavage of a single dose or multiple doses’ of ethanol induces only hepatic steatosis with a slight elevation in serum ALT and AST enzymes[[89](#_ENREF_89),[92-94](#_ENREF_92)]. Administration of various concentrations of ethanol in drinking water given as the only water source for longer-term periods has been shown to cause immune abnormalities and mild steatosis, but has little effect on serum ALT/ AST levels and liver inflammation[[69](#_ENREF_69),[71](#_ENREF_71)].

# STRATEGIES FOR THE FUTURE: HUMANIZED RODENT MODELS

The development of animal models of ALD has led to remarkable progress in the study of ALD over the last 6 decades. However, many of the models described have intrinsic weaknesses and do not fully recapitulate each stage and facet of human ALD. Following ingestion, ethanol is processed through the classical drug disposition routes: Absorption, Distribution, Metabolism and Excretion (ADME). Multiple factors and systems participate in this complex process and can affect, directly and indirectly, the pathogenesis and final outcome of ALD. Due to obvious species differences in physiology and pathology between rodents and humans, translation of results from rats or mice to humans is problematic. However, next generation experimental animals having certain features of human physiology are being developed that can better resemble the effects of disease in the human body.

The concept of “humanized rodent models” refers to mice or rats engrafted with functional human cells and tissues. Human cell and tissue types used in the development of humanized rodents include: Immune cells, hepatocytes, skin tissue, pancreatic islets, uterine endometrium, and neural cells[[95](#_ENREF_95)]. Humanized liver in experimental animals has become an attractive target due to the high regenerative potential of the liver. Early attempts using isolated hepatocytes in rodent models in the 1970s. shifted gradually from ectopic transplantation to in-liver engraftment[[96-100](#_ENREF_96)]. However, one major difficulty preventing these models from becoming effective therapies, is that numbers of functional repopulated hepatocytes after transplantation are still insufficient[[101](#_ENREF_101)]. In the 1990s, breakthroughs came with the introduction of several transgenic mouse lines. The first model was developed by Sandgren *et al*[[102](#_ENREF_102)] with exclusive expression of a protease, urokinase plasminogen activator (uPA) in hepatocytes. Overturf *et al*[[103](#_ENREF_103)] developed a mouse model which targeted disruption of fumarylacetoacetate hydrolase (Fah) - regulated by 2-cyclohexane-1,3-dione (NTBC). With their extraordinary capacity for repopulation of hepatocytes, the engraftment efficiency of transplanted hepatocytes in transgenic models was substantially enhanced compared with normal mice[[104](#_ENREF_104)].

Humanized animal models offer a novel approach, with tremendous opportunity to explore ALD, and to produce more reliable and robust data, that will ultimately be easier to translate from bench to bedside. For example, Cederbaum *et al*[[105](#_ENREF_105)] employed humanized CYP2E1 knock-in mice and discovered significantly elevated liver damage in this group after 3 wk of ethanol feeding, suggesting a major role of CYP2E1 in alcoholic steatosis and oxidant stress. However, there is still a long way before humanized rodent models can become a single, standard model for ALD study. Major challenges include the residual host innate immune system, as well as impaired differentiation and maturation of the human immune cell population due to, for example, differences between human and mouse cytokines. However, these drawbacks will not prevent humanized animal model from being viewed as a promising strategy for the future.

# CONCLUSION

Alcoholism is now recognized as a major global health issue. Health and socio-economic consequences of alcohol consumption represent a heavy burden worldwide. Although significant progress has been made in gaining better knowledge on the mechanisms and pathology of ALD, many features of ALD are unknown, and require further investigation, ideally with animal models that more effectively mimic human ALD.

Nonetheless, the development of ALD models in rodent has also undergone a significant evolution in terms of representing different stages of human ALD. The early *ad libitum* model revealed liver damage after alcohol administration but have the major limitation of natural aversion in rodent. By adding isocaloric ethanol into the diet to keep nutritional balance, the development of the LDC diet successfully overcame the aversion issue and brought the study of ALD into a new era. The TF model then allowed more control of ethanol intake - effectively increasing liver damage following large amount of alcohol infusion. However, current ALD animal models fail to replicate the all-round spectrum of ALD in patients, particularly ALD in advanced stages. As mentioned, 20%-40% of heavy drinkers tend to develop ALD with severe alcoholic hepatitis, liver fibrosis and cirrhosis or even HCC - after 10 years of excessive alcohol consumption. In contrast, the major change in rodent after ethanol-only application with all models is restricted to hepatic steatosis, even with long-term feeding. Importantly, fibrosis or cirrhosis only appears when secondary insults to the liver have been employed.

In the future, an ideal model of ALD in rodent would effectively mimic, step-wise, each stage of how alcohol adversely affects the liver in humans. Key facets of such a model would address processes such as: Ethanol metabolism/ ADME, oxidative stress, ROS production and immune system activation. These are crucial events particularly in advanced fibrotic liver disease. Presently, rodent models remain useful tools for us to improve our knowledge of ALD. Although differences in the degree and stages of alcoholic liver injury exist among rats, mice and humans’ - data acquisition and translational relevance will be greatly enhanced with the development of new and improved animal models of ALD.

# REFERENCES

1 **Lieber CS**, Jones DP, Decarli LM. Effects of prolonged ethanol intake: production of fatty liver despite adequate diets. *J Clin Invest* 1965; **44**: 1009-1021 [PMID: 14322019 DOI: 10.1172/JCI105200]

2 **Gao B**, Bataller R. Alcoholic liver disease: pathogenesis and new therapeutic targets. *Gastroenterology* 2011; **141**: 1572-1585 [PMID: 21920463 DOI: 10.1053/j.gastro.2011.09.002]

3 **Louvet A**, Mathurin P. Alcoholic liver disease: mechanisms of injury and targeted treatment. *Nat Rev Gastroenterol Hepatol* 2015; **12**: 231-242 [PMID: 25782093 DOI: 10.1038/nrgastro.2015.35]

4 **Lieber CS**. Metabolism of alcohol. *Clin Liver Dis* 2005; **9**: 1-35 [PMID: 15763227 DOI: 10.1016/j.cld.2004.10.005]

5 **Cederbaum AI**. Cytochrome P450 2E1-dependent oxidant stress and upregulation of anti-oxidant defense in liver cells. *J Gastroenterol Hepatol* 2006; **21** Suppl 3: S22-S25 [PMID: 16958665 DOI: 10.1111/j.1440-1746.2006.04595.x]

6 **Cederbaum AI**. Alcohol metabolism. *Clin Liver Dis* 2012; **16**: 667-685 [PMID: 23101976 DOI: 10.1016/j.cld.2012.08.002]

7 **Espina N**, Lima V, Lieber CS, Garro AJ. In vitro and in vivo inhibitory effect of ethanol and acetaldehyde on O6-methylguanine transferase. *Carcinogenesis* 1988; **9**: 761-766 [PMID: 3365837]

8 **Müller A**, Sies H. Role of alcohol dehydrogenase activity and the acetaldehyde in ethanol- induced ethane and pentane production by isolated perfused rat liver. *Biochem J* 1982; **206**: 153-156 [PMID: 6751324]

9 **Lieber CS**, Baraona E, Hernández-Muñoz R, Kubota S, Sato N, Kawano S, Matsumura T, Inatomi N. Impaired oxygen utilization. A new mechanism for the hepatotoxicity of ethanol in sub-human primates. *J Clin Invest* 1989; **83**: 1682-1690 [PMID: 2708529 DOI: 10.1172/JCI114068]

10 **Friedman SL**. Mechanisms of hepatic fibrogenesis. *Gastroenterology* 2008; **134**: 1655-1669 [PMID: 18471545 DOI: 10.1053/j.gastro.2008.03.003]

11 **Bataller R**, Brenner DA. Liver fibrosis. *J Clin Invest* 2005; **115**: 209-218 [PMID: 15690074 DOI: 10.1172/JCI24282]

12 **Cubero FJ**, Urtasun R, Nieto N. Alcohol and liver fibrosis. *Semin Liver Dis* 2009; **29**: 211-221 [PMID: 19387920 DOI: 10.1055/s-0029-1214376]

13 **Mello T**, Ceni E, Surrenti C, Galli A. Alcohol induced hepatic fibrosis: role of acetaldehyde. *Mol Aspects Med* 2008; **29**: 17-21 [PMID: 18164754 DOI: 10.1016/j.mam.2007.10.001]

14 **Thurman RG**, Bradford BU, Iimuro Y, Knecht KT, Connor HD, Adachi Y, Wall C, Arteel GE, Raleigh JA, Forman DT, Mason RP. Role of Kupffer cells, endotoxin and free radicals in hepatotoxicity due to prolonged alcohol consumption: studies in female and male rats. *J Nutr* 1997; **127**: 903S-906S [PMID: 9164260 DOI: 10.1093/jn/127.5.903S]

15 **Szabo G**, Bala S. Alcoholic liver disease and the gut-liver axis. *World J Gastroenterol* 2010; **16**: 1321-1329 [PMID: 20238398]

16 **Seki E**, De Minicis S, Osterreicher CH, Kluwe J, Osawa Y, Brenner DA, Schwabe RF. TLR4 enhances TGF-beta signaling and hepatic fibrosis. *Nat Med* 2007; **13**: 1324-1332 [PMID: 17952090 DOI: 10.1038/nm1663]

17 **Jagavelu K**, Routray C, Shergill U, O'Hara SP, Faubion W, Shah VH. Endothelial cell toll-like receptor 4 regulates fibrosis-associated angiogenesis in the liver. *Hepatology* 2010; **52**: 590-601 [PMID: 20564354 DOI: 10.1002/hep.23739]

18 **Inokuchi S**, Tsukamoto H, Park E, Liu ZX, Brenner DA, Seki E. Toll-like receptor 4 mediates alcohol-induced steatohepatitis through bone marrow-derived and endogenous liver cells in mice. *Alcohol Clin Exp Res* 2011; **35**: 1509-1518 [PMID: 21463341 DOI: 10.1111/j.1530-0277.2011.01487.x]

19 **Morgan TR**, Mandayam S, Jamal MM. Alcohol and hepatocellular carcinoma. *Gastroenterology* 2004; **127**: S87-S96 [PMID: 15508108]

20 **McKillop IH**, Schrum LW. Role of alcohol in liver carcinogenesis. *Semin Liver Dis* 2009; **29**: 222-232 [PMID: 19387921 DOI: 10.1055/s-0029-1214377]

21 **Guerrini A**. Experimenting with Humans and Animals: From Galen to Animal Rights. Baltimore: Johns Hopkins University Press, 2003

22 **Gregory A**. Harvey's Heart: The Discovery of Blood Circulation. New York: Totem Books, 2001

23 **Shackelford J**. William Harvey and the Mechanics of the Heart. New York: Oxford University Press, 2003

24 **Butura A**, Nilsson K, Morgan K, Morgan TR, French SW, Johansson I, Schuppe-Koistinen I, Ingelman-Sundberg M. The impact of CYP2E1 on the development of alcoholic liver disease as studied in a transgenic mouse model. *J Hepatol* 2009; **50**: 572-583 [PMID: 19157621 DOI: 10.1016/j.jhep.2008.10.020]

25 **Arvola A**, Forsander O. Comparison between water and alcohol consumption in six animal species infree choice experiments. *Nature* 1961; **191**: 819-820 [PMID: 13684626]

26 **Lieber CS**, Leo MA, Mak KM, DeCarli LM, Sato S. Choline fails to prevent liver fibrosis in ethanol-fed baboons but causes toxicity. *Hepatology* 1985; **5**: 561-572 [PMID: 4018729]

27 **Brandon-Warner E**, Schrum LW, Schmidt CM, McKillop IH. Rodent models of alcoholic liver disease: of mice and men. *Alcohol* 2012; **46**: 715-725 [PMID: 22960051 DOI: 10.1016/j.alcohol.2012.08.004]

28 **Bertola A**, Mathews S, Ki SH, Wang H, Gao B. Mouse model of chronic and binge ethanol feeding (the NIAAA model). *Nat Protoc* 2013; **8**: 627-637 [PMID: 23449255 DOI: 10.1038/nprot.2013.032]

29 **Holmes RS**, Duley JA, Algar EM, Mather PB, Rout UK. Biochemical and genetic studies on enzymes of alcohol metabolism: the mouse as a model organism for human studies. *Alcohol Alcohol* 1986; **21**: 41-56 [PMID: 2937415]

30 **Mestas J**, Hughes CC. Of mice and not men: differences between mouse and human immunology. *J Immunol* 2004; **172**: 2731-2738 [PMID: 14978070]

31 **Copeland S**, Warren HS, Lowry SF, Calvano SE, Remick D; Inflammation and the Host Response to Injury Investigators. Acute inflammatory response to endotoxin in mice and humans. *Clin Diagn Lab Immunol* 2005; **12**: 60-67 [PMID: 15642986 DOI: 10.1128/CDLI.12.1.60-67.2005]

32 **Eng MY**, Luczak SE, Wall TL. ALDH2, ADH1B, and ADH1C genotypes in Asians: a literature review. *Alcohol Res Health* 2007; **30**: 22-27 [PMID: 17718397]

33 **Tsuchiya M**, Ji C, Kosyk O, Shymonyak S, Melnyk S, Kono H, Tryndyak V, Muskhelishvili L, Pogribny IP, Kaplowitz N, Rusyn I. Interstrain differences in liver injury and one-carbon metabolism in alcohol-fed mice. *Hepatology* 2012; **56**: 130-139 [PMID: 22307928 DOI: 10.1002/hep.25641]

34 **Denucci SM**, Tong M, Longato L, Lawton M, Setshedi M, Carlson RI, Wands JR, de la Monte SM. Rat strain differences in susceptibility to alcohol-induced chronic liver injury and hepatic insulin resistance. *Gastroenterol Res Pract* 2010; **2010**: [PMID: 20814553 DOI: 10.1155/2010/312790]

35 **DeNoble VJ**, Mele PC, Porter JH. Intravenous self-administration of pentobarbital and ethanol in rats. *Pharmacol Biochem Behav* 1985; **23**: 759-763 [PMID: 4080762]

36 **Zhang P**, Bagby GJ, Xie M, Stoltz DA, Summer WR, Nelson S. Acute ethanol intoxication inhibits neutrophil beta2-integrin expression in rats during endotoxemia. *Alcohol Clin Exp Res* 1998; **22**: 135-141 [PMID: 9514298]

37 **Slawecki CJ**, Somes C, Ehlers CL. Effects of prolonged ethanol exposure on neurophysiological measures during an associative learning paradigm. *Drug Alcohol Depend* 2000; **58**: 125-132 [PMID: 10669063]

38 **Enomoto N**, Ikejima K, Bradford B, Rivera C, Kono H, Brenner DA, Thurman RG. Alcohol causes both tolerance and sensitization of rat Kupffer cells via mechanisms dependent on endotoxin. *Gastroenterology* 1998; **115**: 443-451 [PMID: 9679050]

39 **Lieber CS,** Jones DP, Medelson J, DeCarli LM. Fatty liver, hyperlipemia and hyperuricemia produced by prolonged alcohol consumption, despite adequate dietary intake. Trans Assoc Am Physicians 1963; 76: 289-300

40 **Best CH**, Hartroft WS. Liver damage produced by feeding alcohol or sugar and its prevention by choline. *Br Med J* 1949; **2**: 1002-1006, pl [PMID: 15393035]

41 **Lieber CS**, DeCarli LM. Study of agents for the prevention of the fatty liver produced by prolonged alcohol intake. *Gastroenterology* 1966; **50**: 316-322 [PMID: 5948329]

42 **DeCarli LM**, Lieber CS. Fatty liver in the rat after prolonged intake of ethanol with a nutritionally adequate new liquid diet. *J Nutr* 1967; **91**: 331-336 [PMID: 6021815 DOI: 10.1093/jn/91.3\_Suppl.331]

43 **Lieber CS**, DeCarli LM. Ethanol oxidation by hepatic microsomes: adaptive increase after ethanol feeding. *Science* 1968; **162**: 917-918 [PMID: 4386718]

44 **Lieber CS**, DeCarli LM. The feeding of alcohol in liquid diets: two decades of applications and 1982 update. *Alcohol Clin Exp Res* 1982; **6**: 523-531 [PMID: 6758624]

45 **Lieber CS**, DeCarli LM. Liquid diet technique of ethanol administration: 1989 update. *Alcohol Alcohol* 1989; **24**: 197-211 [PMID: 2667528]

46 **de la M Hall P**, Lieber CS, DeCarli LM, French SW, Lindros KO, Järveläinen H, Bode C, Parlesak A, Bode JC. Models of alcoholic liver disease in rodents: a critical evaluation. *Alcohol Clin Exp Res* 2001; **25**: 254S-261S [PMID: 11391080]

47 **Guo F**, Zheng K, Benedé-Ubieto R, Cubero FJ, Nevzorova YA. The Lieber-DeCarli Diet-A Flagship Model for Experimental Alcoholic Liver Disease. *Alcohol Clin Exp Res* 2018; **42**: 1828-1840 [PMID: 30025151 DOI: 10.1111/acer.13840]

48 **Nevzorova YA**, Cubero FJ, Hu W, Hao F, Haas U, Ramadori P, Gassler N, Hoss M, Strnad P, Zimmermann HW, Tacke F, Trautwein C, Liedtke C. Enhanced expression of c-myc in hepatocytes promotes initiation and progression of alcoholic liver disease. *J Hepatol* 2016; **64**: 628-640 [PMID: 26576483 DOI: 10.1016/j.jhep.2015.11.005]

49 **Tammen SA**, Dolnikowski GG, Ausman LM, Liu Z, Sauer J, Friso S, Choi SW. Aging and alcohol interact to alter hepatic DNA hydroxymethylation. *Alcohol Clin Exp Res* 2014; **38**: 2178-2185 [PMID: 25070523 DOI: 10.1111/acer.12477]

50 **Park JK**, Shao M, Kim MY, Baik SK, Cho MY, Utsumi T, Satoh A, Ouyang X, Chung C, Iwakiri Y. An endoplasmic reticulum protein, Nogo-B, facilitates alcoholic liver disease through regulation of kupffer cell polarization. *Hepatology* 2017; **65**: 1720-1734 [PMID: 28090670 DOI: 10.1002/hep.29051]

51 **Ambade A**, Satishchandran A, Gyongyosi B, Lowe P, Szabo G. Adult mouse model of early hepatocellular carcinoma promoted by alcoholic liver disease. *World J Gastroenterol* 2016; **22**: 4091-4108 [PMID: 27122661 DOI: 10.3748/wjg.v22.i16.4091]

52 **Alund AW**, Mercer KE, Pulliam CF, Suva LJ, Chen JR, Badger TM, Ronis MJ. Partial Protection by Dietary Antioxidants Against Ethanol-Induced Osteopenia and Changes in Bone Morphology in Female Mice. *Alcohol Clin Exp Res* 2017; **41**: 46-56 [PMID: 27987315 DOI: 10.1111/acer.13284]

53 **Bang CS**, Hong SH, Suk KT, Kim JB, Han SH, Sung H, Kim EJ, Kim MJ, Kim MY, Baik SK, Kim DJ. Effects of Korean Red Ginseng (Panax ginseng), urushiol (Rhus vernicifera Stokes), and probiotics (Lactobacillus rhamnosus R0011 and Lactobacillus acidophilus R0052) on the gut-liver axis of alcoholic liver disease. *J Ginseng Res*2014; **38**: 167-172 [PMID: 25378990 DOI: 10.1016/j.jgr.2014.04.002]

54 **Varghese J**, James JV, Sagi S, Chakraborty S, Sukumaran A, Ramakrishna B, Jacob M. Decreased hepatic iron in response to alcohol may contribute to alcohol-induced suppression of hepcidin. *Br J Nutr* 2016; **115**: 1978-1986 [PMID: 27080262 DOI: 10.1017/S0007114516001197]

55 **Sun Q**, Zhong W, Zhang W, Zhou Z. Defect of mitochondrial respiratory chain is a mechanism of ROS overproduction in a rat model of alcoholic liver disease: role of zinc deficiency. *Am J Physiol Gastrointest Liver Physiol* 2016; **310**: G205-G214 [PMID: 26585415 DOI: 10.1152/ajpgi.00270.2015]

56 **Okazaki S**, Nagoya S, Tateda K, Katada R, Mizuo K, Watanabe S, Yamashita T, Matsumoto H. Experimental rat model for alcohol-induced osteonecrosis of the femoral head. *Int J Exp Pathol* 2013; **94**: 312-319 [PMID: 24020403 DOI: 10.1111/iep.12035]

57 **Cubero FJ**, Nieto N. Ethanol and arachidonic acid synergize to activate Kupffer cells and modulate the fibrogenic response via tumor necrosis factor alpha, reduced glutathione, and transforming growth factor beta-dependent mechanisms. *Hepatology* 2008; **48**: 2027-2039 [PMID: 19003881 DOI: 10.1002/hep.22592]

58 **Leo MA**, Lieber CS. Hepatic fibrosis after long-term administration of ethanol and moderate vitamin A supplementation in the rat. *Hepatology* 1983; **3**: 1-11 [PMID: 6681608]

59 **Zakhari S**, Li TK. Determinants of alcohol use and abuse: Impact of quantity and frequency patterns on liver disease. *Hepatology* 2007; **46**: 2032-2039 [PMID: 18046720 DOI: 10.1002/hep.22010]

60 **Aroor AR**, Jackson DE, Shukla SD. Elevated activation of ERK1 and ERK2 accompany enhanced liver injury following alcohol binge in chronically ethanol-fed rats. *Alcohol Clin Exp Res* 2011; **35**: 2128-2138 [PMID: 21790671 DOI: 10.1111/j.1530-0277.2011.01577.x]

61 **Marhenke S**, Buitrago-Molina LE, Endig J, Orlik J, Schweitzer N, Klett S, Longerich T, Geffers R, Sánchez Muñoz A, Dorrell C, Katz SF, Lechel A, Weng H, Krech T, Lehmann U, Dooley S, Rudolph KL, Manns MP, Vogel A. p21 promotes sustained liver regeneration and hepatocarcinogenesis in chronic cholestatic liver injury. *Gut*2014; **63**: 1501-1512 [PMID: 24092862 DOI: 10.1136/gutjnl-2013-304829]

62 **Shukla SD**, Pruett SB, Szabo G, Arteel GE. Binge ethanol and liver: new molecular developments. *Alcohol Clin Exp Res* 2013; **37**: 550-557 [PMID: 23347137 DOI: 10.1111/acer.12011]

63 **Rafacho BP**, Stice CP, Liu C, Greenberg AS, Ausman LM, Wang XD. Inhibition of diethylnitrosamine-initiated alcohol-promoted hepatic inflammation and precancerous lesions by flavonoid luteolin is associated with increased sirtuin 1 activity in mice. *Hepatobiliary Surg Nutr* 2015; **4**: 124-134 [PMID: 26005679 DOI: 10.3978/j.issn.2304-3881.2014.08.06]

64 **Muñoz NM**, Katz LH, Shina JH, Gi YJ, Menon VK, Gagea M, Rashid A, Chen J, Mishra L. Generation of a mouse model of T-cell lymphoma based on chronic LPS challenge and TGF-β signaling disruption. *Genes Cancer* 2014; **5**: 348-352 [PMID: 25352951 DOI: 10.18632/genesandcancer.32]

65 **Karaca G**, Xie G, Moylan C, Swiderska-Syn M, Guy CD, Krüger L, Machado MV, Choi SS, Michelotti GA, Burkly LC, Diehl AM. Role of Fn14 in acute alcoholic steatohepatitis in mice. *Am J Physiol Gastrointest Liver Physiol* 2015; **308**: G325-G334 [PMID: 25524063 DOI: 10.1152/ajpgi.00429.2013]

66 **McCuskey RS**, Bethea NW, Wong J, McCuskey MK, Abril ER, Wang X, Ito Y, DeLeve LD. Ethanol binging exacerbates sinusoidal endothelial and parenchymal injury elicited by acetaminophen. *J Hepatol* 2005; **42**: 371-377 [PMID: 15710220 DOI: 10.1016/j.jhep.2004.11.033]

67 **Brandon-Warner E**, Walling TL, Schrum LW, McKillop IH. Chronic ethanol feeding accelerates hepatocellular carcinoma progression in a sex-dependent manner in a mouse model of hepatocarcinogenesis. *Alcohol Clin Exp Res* 2012; **36**: 641-653 [PMID: 22017344 DOI: 10.1111/j.1530-0277.2011.01660.x]

68 **Keegan A**, Martini R, Batey R. Ethanol-related liver injury in the rat: a model of steatosis, inflammation and pericentral fibrosis. *J Hepatol* 1995; **23**: 591-600 [PMID: 8583149]

69 **Cook RT**, Schlueter AJ, Coleman RA, Tygrett L, Ballas ZK, Jerrells TR, Nashelsky MB, Ray NB, Haugen TH, Waldschmidt TJ. Thymocytes, pre-B cells, and organ changes in a mouse model of chronic ethanol ingestion--absence of subset-specific glucocorticoid-induced immune cell loss. *Alcohol Clin Exp Res* 2007; **31**: 1746-1758 [PMID: 17681030 DOI: 10.1111/j.1530-0277.2007.00478.x]

70 **Song M**, Chen T, Prough RA, Cave MC, McClain CJ. Chronic Alcohol Consumption Causes Liver Injury in High-Fructose-Fed Male Mice Through Enhanced Hepatic Inflammatory Response. *Alcohol Clin Exp Res* 2016; **40**: 518-528 [PMID: 26858005 DOI: 10.1111/acer.12994]

71 **Meadows GG**, Blank SE, Duncan DD. Influence of ethanol consumption on natural killer cell activity in mice. *Alcohol Clin Exp Res* 1989; **13**: 476-479 [PMID: 2679200]

72 **McCaskill ML**, Hottor HT, Sapkota M, Wyatt TA. Dietary diallyl disulfide supplementation attenuates ethanol-mediated pulmonary vitamin D speciate depletion in C57Bl/6 mice. *BMC Nutr* 2015; **1**: [PMID: 27536382 DOI: 10.1186/s40795-015-0012-z]

73 **Tan TC**, Crawford DH, Jaskowski LA, Subramaniam VN, Clouston AD, Crane DI, Bridle KR, Anderson GJ, Fletcher LM. Excess iron modulates endoplasmic reticulum stress-associated pathways in a mouse model of alcohol and high-fat diet-induced liver injury. *Lab Invest* 2013; **93**: 1295-1312 [PMID: 24126888 DOI: 10.1038/labinvest.2013.121]

74 **Abraham P**, Wilfred G, Ramakrishna B. Oxidative damage to the hepatocellular proteins after chronic ethanol intake in the rat. *Clin Chim Acta* 2002; **325**: 117-125 [PMID: 12367775]

75 **Chae HB**, Jang LC, Park SM, Son BR, Sung R, Choi JW. [An experimental model of hepatic fibrosis induced by alcohol and CCl4: can the lipopolysaccharide prevent liver injury induced by alcohol and CCl4?]. *Taehan Kan Hakhoe Chi* 2002; **8**: 173-178 [PMID: 12499803]

76 **Tsukamoto H**, Reidelberger RD, French SW, Largman C. Long-term cannulation model for blood sampling and intragastric infusion in the rat. *Am J Physiol* 1984; **247**: R595-R599 [PMID: 6433728]

77 **Ueno A**, Lazaro R, Wang PY, Higashiyama R, Machida K, Tsukamoto H. Mouse intragastric infusion (iG) model. *Nat Protoc* 2012; **7**: 771-781 [PMID: 22461066 DOI: 10.1038/nprot.2012.014]

78 **Tsukamoto H**, French SW, Benson N, Delgado G, Rao GA, Larkin EC, Largman C. Severe and progressive steatosis and focal necrosis in rat liver induced by continuous intragastric infusion of ethanol and low fat diet. *Hepatology* 1985; **5**: 224-232 [PMID: 3979954]

79 **Tsukamoto H**, Towner SJ, Ciofalo LM, French SW. Ethanol-induced liver fibrosis in rats fed high fat diet. *Hepatology* 1986; **6**: 814-822 [PMID: 3758935]

80 **Tsukamoto H**, Horne W, Kamimura S, Niemelä O, Parkkila S, Ylä-Herttuala S, Brittenham GM. Experimental liver cirrhosis induced by alcohol and iron. *J Clin Invest* 1995; **96**: 620-630 [PMID: 7615836 DOI: 10.1172/JCI118077]

81 **Nanji AA**, French SW. Animal models of alcoholic liver disease--focus on the intragastric feeding model. *Alcohol Res Health* 2003; **27**: 325-330 [PMID: 15540804]

82 **French SW**. Intragastric ethanol infusion model for cellular and molecular studies of alcoholic liver disease. *J Biomed Sci* 2001; **8**: 20-27 [PMID: 11173972 DOI: 10.1159/000054009]

83 **Nanji AA**, Mendenhall CL, French SW. Beef fat prevents alcoholic liver disease in the rat. *Alcohol Clin Exp Res* 1989; **13**: 15-19 [PMID: 2646971]

84 **Deng QG**, She H, Cheng JH, French SW, Koop DR, Xiong S, Tsukamoto H. Steatohepatitis induced by intragastric overfeeding in mice. *Hepatology* 2005; **42**: 905-914 [PMID: 16175602 DOI: 10.1002/hep.20877]

85 **Cohen JI**, Roychowdhury S, McMullen MR, Stavitsky AB, Nagy LE. Complement and alcoholic liver disease: role of C1q in the pathogenesis of ethanol-induced liver injury in mice. *Gastroenterology* 2010; **139**: 664-674, 674.e1 [PMID: 20416309 DOI: 10.1053/j.gastro.2010.04.041]

86 **Mandrekar P**, Ambade A, Lim A, Szabo G, Catalano D. An essential role for monocyte chemoattractant protein-1 in alcoholic liver injury: regulation of proinflammatory cytokines and hepatic steatosis in mice. *Hepatology* 2011; **54**: 2185-2197 [PMID: 21826694 DOI: 10.1002/hep.24599]

87 **Hu M**, Wang F, Li X, Rogers CQ, Liang X, Finck BN, Mitra MS, Zhang R, Mitchell DA, You M. Regulation of hepatic lipin-1 by ethanol: role of AMP-activated protein kinase/sterol regulatory element-binding protein 1 signaling in mice. *Hepatology* 2012; **55**: 437-446 [PMID: 21953514 DOI: 10.1002/hep.24708]

88 **Liangpunsakul S**, Rahmini Y, Ross RA, Zhao Z, Xu Y, Crabb DW. Imipramine blocks ethanol-induced ASMase activation, ceramide generation, and PP2A activation, and ameliorates hepatic steatosis in ethanol-fed mice. *Am J Physiol Gastrointest Liver Physiol* 2012; **302**: G515-G523 [PMID: 22194417 DOI: 10.1152/ajpgi.00455.2011]

89 **Leung TM**, Lu Y, Yan W, Morón-Concepción JA, Ward SC, Ge X, Conde de la Rosa L, Nieto N. Argininosuccinate synthase conditions the response to acute and chronic ethanol-induced liver injury in mice. *Hepatology* 2012; **55**: 1596-1609 [PMID: 22213272 DOI: 10.1002/hep.25543]

90 **Xu J**, Lai KKY, Verlinsky A, Lugea A, French SW, Cooper MP, Ji C, Tsukamoto H. Synergistic steatohepatitis by moderate obesity and alcohol in mice despite increased adiponectin and p-AMPK. *J Hepatol* 2011; **55**: 673-682 [PMID: 21256905 DOI: 10.1016/j.jhep.2010.12.034]

91 **Kisseleva T**, Cong M, Paik Y, Scholten D, Jiang C, Benner C, Iwaisako K, Moore-Morris T, Scott B, Tsukamoto H, Evans SM, Dillmann W, Glass CK, Brenner DA. Myofibroblasts revert to an inactive phenotype during regression of liver fibrosis. *Proc Natl Acad Sci U S A* 2012; **109**: 9448-9453 [PMID: 22566629 DOI: 10.1073/pnas.1201840109]

92 **Zhou Z**, Wang L, Song Z, Lambert JC, McClain CJ, Kang YJ. A critical involvement of oxidative stress in acute alcohol-induced hepatic TNF-alpha production. *Am J Pathol* 2003; **163**: 1137-1146 [PMID: 12937155]

93 **Beier JI**, Kaiser JP, Guo L, Martínez-Maldonado M, Arteel GE. Plasminogen activator inhibitor-1 deficient mice are protected from angiotensin II-induced fibrosis. *Arch Biochem Biophys* 2011; **510**: 19-26 [PMID: 21501583 DOI: 10.1016/j.abb.2011.04.001]

94 **Kao E**, Shinohara M, Feng M, Lau MY, Ji C. Human immunodeficiency virus protease inhibitors modulate Ca2+ homeostasis and potentiate alcoholic stress and injury in mice and primary mouse and human hepatocytes. *Hepatology* 2012; **56**: 594-604 [PMID: 22407670 DOI: 10.1002/hep.25702]

95 **Fujiwara S**. Humanized mice: A brief overview on their diverse applications in biomedical research. *J Cell Physiol* 2018; **233**: 2889-2901 [PMID: 28543438 DOI: 10.1002/jcp.26022]

96 **Matas AJ**, Sutherland DE, Steffes MW, Mauer SM, Sowe A, Simmons RL, Najarian JS. Hepatocellular transplantation for metabolic deficiencies: decrease of plasms bilirubin in Gunn rats. *Science* 1976; **192**: 892-894 [PMID: 818706]

97 **Jirtle RL**, Biles C, Michalopoulos G. Morphologic and histochemical analysis of hepatocytes transplanted into syngeneic hosts. *Am J Pathol* 1980; **101**: 115-126 [PMID: 6108719]

98 **Kusano M**, Mito M. Observations on the fine structure of long-survived isolated hepatocytes inoculated into rat spleen. *Gastroenterology* 1982; **82**: 616-628 [PMID: 7060884]

99 **Gupta S**, Chowdhury NR, Jagtiani R, Gustin K, Aragona E, Shafritz DA, Chowdhury JR, Burk RD. A novel system for transplantation of isolated hepatocytes utilizing HBsAg-producing transgenic donor cells. *Transplantation* 1990; **50**: 472-475 [PMID: 2402796]

100 **Ponder KP**, Gupta S, Leland F, Darlington G, Finegold M, DeMayo J, Ledley FD, Chowdhury JR, Woo SL. Mouse hepatocytes migrate to liver parenchyma and function indefinitely after intrasplenic transplantation. *Proc Natl Acad Sci USA* 1991; **88**: 1217-1221 [PMID: 1899924]

101 **Shafritz DA**, Oertel M. Model systems and experimental conditions that lead to effective repopulation of the liver by transplanted cells. *Int J Biochem Cell Biol*2011; **43**: 198-213 [PMID: 20080205 DOI: 10.1016/j.biocel.2010.01.013]

102 **Sandgren EP**, Palmiter RD, Heckel JL, Daugherty CC, Brinster RL, Degen JL. Complete hepatic regeneration after somatic deletion of an albumin-plasminogen activator transgene. *Cell* 1991; **66**: 245-256 [PMID: 1713128]

103 **Overturf K**, Al-Dhalimy M, Tanguay R, Brantly M, Ou CN, Finegold M, Grompe M. Hepatocytes corrected by gene therapy are selected in vivo in a murine model of hereditary tyrosinaemia type I. *Nat Genet* 1996; **12**: 266-273 [PMID: 8589717 DOI: 10.1038/ng0396-266]

104 **Rhim JA**, Sandgren EP, Degen JL, Palmiter RD, Brinster RL. Replacement of diseased mouse liver by hepatic cell transplantation. *Science* 1994; **263**: 1149-1152 [PMID: 8108734]

105 **Lu Y**, Wu D, Wang X, Ward SC, Cederbaum AI. Chronic alcohol-induced liver injury and oxidant stress are decreased in cytochrome P4502E1 knockout mice and restored in humanized cytochrome P4502E1 knock-in mice. *Free Radic Biol Med* 2010; **49**: 1406-1416 [PMID: 20692331 DOI: 10.1016/j.freeradbiomed.2010.07.026]

106 **Kwon HJ**, Won YS, Park O, Chang B, Duryee MJ, Thiele GE, Matsumoto A, Singh S, Abdelmegeed MA, Song BJ, Kawamoto T, Vasiliou V, Thiele GM, Gao B. Aldehyde dehydrogenase 2 deficiency ameliorates alcoholic fatty liver but worsens liver inflammation and fibrosis in mice. *Hepatology* 2014; **60**: 146-157 [PMID: 24492981 DOI: 10.1002/hep.27036]

**P-Reviewer:** Ji G, Kim DJ

**S-Editor:** Ma RY **L-Editor:** **E-Editor:**

**Specialty type:** Gastroenterology and hepatology

**Country of origin:** Spain

**Peer-review report classification**


Grade A (Excellent): 0

Grade B (Very good): B

Grade C (Good): C

Grade D (Fair): 0

Grade E (Poor): 0



**Figure 1 Alcohol metabolism in hepatocytes.** Ethanol is oxidized to acetaldehyde through action of the enzyme alcohol dehydrogenase and cytochrome P450 isoenzyme 2E1 a major component of the microsomal enzyme oxidation system. Acetaldehyde is subsequently metabolized to acetate by acetaldehyde dehydrogenase. In this process coenzyme nicotinamide adenine dinucleotide is reduced to coenzyme nicotinamide adenine dinucleotide reduced. The metabolism of ethanol increases generation of reactive oxygen species, including hydroxyethyl, superoxide anion and hydroxyl radicals, which contribute to oxidative stress and also can react with other cellular molecules, forming adducts (proteins, lipids or DNA). ADH: Alcohol dehydrogenase; CYP2E1: Cytochrome P450 isoenzyme 2E1; MEOS: Microsomal enzyme oxidation system; ALDH: Acetaldehyde dehydrogenase; NAD+: Nicotinamide adenine dinucleotide; NADH: Nicotinamide adenine dinucleotide reduced; ROS: Reactive oxygen species.

**Figure 2 Alcohol induces fatty liver disease.** Alcohol causes the accumulation of fat droplets in hepatocytes increasing the lipogenesis and decreasing the fatty acid oxidation. CYP2E1: Cytochrome P450 isoenzyme 2E1; ROS: Reactive oxygen species.

**Table 1 Comparison of experimental models of alcoholic liver disease**

|  |  |  |  |
| --- | --- | --- | --- |
| **Models** | **Animal model** | **Characteristics** | **Advantages and disadvantages** |
| Lieber-DeCarli liquid diet[[27](#_ENREF_27),[28](#_ENREF_28)] | Rat/Mice | Chronic ethanol feeding (4-12 wk) | Easy to perform  Marked elevation of ALT  Short term feeding with no mortality rate  No liver fibrosis |
| Rat/Mice | Chronic ethanol feeding + single/multiple binges (4-6 wk) | Easy to perform  Marked elevation of ALT and marked steatosis  Long term feeding + multiple binges with a high mortality rate  No liver fibrosis |
| Rat/Mice | **+** Second hit: DEN, LPS, CCl4, APAP (4-12 wk) | Easy to perform  Marked elevation of ALT and marked steatosis  Long term feeding + multiple binges + injection with a high mortality rate  Liver fibrosis |
| Ethanol *ad libitum* feeding [[27](#_ENREF_27),[28](#_ENREF_28)] | Mice | Oral alcohol in drinking water (10 d/1-2 wk) | Easy to perform  Minimal elevation of ALT and mild steatosis  Short-or long-term feeding with no mortality rate  No liver fibrosis |
| The Tsukamoto-French model[[27](#_ENREF_27),[28](#_ENREF_28)] | Rat/Mice | Intragastric infusion (2-3 mo) | Difficult to perform  Requirement for intensive medical care  Marked elevation of ALT and steatosis  Long-term feeding with a high mortality rate  Mild liver fibrosis |
| The NIAA model[[47](#_ENREF_47)] | Mice | LDE + single ethanol binge | Cost and time efficient  High blood alcohol levels  Liver injury  Inflammation  Fatty liver |
| Rat / Mice | LDE + 3 ethanol binges | Cost and time efficient  Increased blood alcohol levels  Augmented liver injury  Increases in ERK1/2 |
| Ethanol + CCl4 treatment[[106](#_ENREF_106)] | Mice | 4% ethanol liquid diet + 2 times IP CCl4 injection per week (8 wk) | Easy to perform  Toxic components  Elevated acetaldehyde levels  Liver fibrosis |

Lieber-DeCarli liquid diet with different variants, ethanol *ad libitum* feeding and the Tsukamoto-French and the NIAA model. ALT: Alcoholic liver disease; DEN: Diethylnitrosamine; LPS: Lipopolysaccharide; CCl4: Carbon tetrachloride; APAP: Acetaminophen; LDE: Lieber-De Carli ethanol diet; IP: Intraperitoneal.